SPECIAL NOTICE
D -- This is a special notice for a vendor fair regarding information technology infrastructure
- Notice Date
- 12/23/2011
- Notice Type
- Special Notice
- NAICS
- 541512
— Computer Systems Design Services
- Contracting Office
- Department of Health and Human Services, Food and Drug Administration, Office of Acquisitions and Grants Services, 5630 Fishers Lane, Room 2129, Rockville, Maryland, 20857-0001
- ZIP Code
- 20857-0001
- Solicitation Number
- FAIR
- Point of Contact
- Beth A. Goldberg, Phone: 3018277153, Jennifer Fagan,
- E-Mail Address
-
beth.goldberg@fda.hhs.gov, jennifer.fagan@fda.hhs.gov
(beth.goldberg@fda.hhs.gov, jennifer.fagan@fda.hhs.gov)
- Small Business Set-Aside
- N/A
- Description
- **** THIS IS NOT A REQUEST FOR PROPOSALS OR A REQUEST FOR QUOTATIONS; IT IS STRICTLY A SPECIAL NOTICE REQUESTING INFORMATION FOR MARKET RESEARCH PURPOSES AND NOTIFYING VENDORS OF A VENDOR FAIR. THIS NOTICE DOES NOT RELATE TO A SPECIFIC REQUIREMENT. NEITHER UNSOLICITED PROPOSALS NOR ANY OTHER KINDS OF OFFERS WILL BE CONSIDERED IN RESPONSE TO THIS SPECIAL NOTE. NO CONTRACT WILL BE AWARDED PURSUANT TO THIS ANNOUNCEMENT. **** 1. SUBJECT: The Food and Drug Administration's Center for Tobacco Products (FDA/CTP) is working toward a vision of a fully integrated data environment that will include electronic interfaces to current data sources and efficient and timely access to data that can be used across programs to facilitate the analysis of complex data sets. The market for this type of fully integrated data environment is quickly evolving. To ensure FDA has access to information on the latest innovations, FDA is surveying the marketplace by requesting information and having a vendor fair. FDA will take the information it obtains from the vendor fair into account as it determines how best to structure and implement its Information Technology Infrastructure. 2. DISCLAIMER: This SPECIAL NOTICE is issued solely to survey the market and does not constitute a solicitation. Neither unsolicited proposals nor any other kind of offers will be considered in response to this NOTICE. Responses to this notice are not offers and will not be accepted by the Government to form a binding contract. Respondents are solely responsible for all expenses associated with responding to this NOTICE. All information received in response to this NOTICE marked as "proprietary" will be handled accordingly. Information provided as a response to the NOTICE will not be returned. FDA/CTP will not entertain any questions concerning the composition, requirements, or the nature of services to be performed under any future request for proposal (RFP). 3. BACKGROUND: FDA is working towards a vision for the development/ modernization/ sustainment of a toolset that will include electronic interfaces to currently available data sources and timely data that can be used by multiple sharing across programs to facilitate the analysis of complex data sets. It is envisioned that such a data set would provide FDA/CTP with an infrastructure that includes centrally managed, end user mobile devices, enterprise licensing agreements (ELAs), enterprise service desks (ESDs), servers and other hardware. Desired key attributes of the toolset that the FDA envisions include: 1. Proven processes, procedures, and technologies to ensure harmonization of data. 2. Proven processes, procedures, and technologies to ensure interoperability between data sources. 3. Proven processes, procedures, and technologies to ensure data processing, categorization, and dissection. 4. Scientifically proven processes, procedures, and technologies to ensure security of intellectual property. 5. Scientifically proven processes, procedures, and technologies to optimize laboratory and capacity utilization. 6. Scientifically proven processes, procedures, and technologies to optimize product test methodology. 7. Proven processes, procedures, and technologies to maximize the assurance of rapid and complete product recalls. 8. Proven processes, procedures, and technologies to facilitate track and trace. 9. Scientifically proven processes, procedures, and technologies to optimize toxicology testing, specifically related to non-cancer endpoints? 10. Proven processes, procedures, and technologies facilitate adverse event reporting. 11. Scientifically proven processes, procedures, and technologies to identify short-term biomarkers of long-term harm (e.g., proteomics, metabolomics). 12. Scientifically proven processes, procedures, and technologies to measure Communication of Health Effects. FDA/CTP seeks information about academic, prototype, developmental, and domestic commercially available products that meet or can be readily modified to meet the requirements discussed above. 4. SUBMISSION INSTRUCTIONS: Responses are due to this SPECIAL NOTICE by 12:00 PM on January 6, 2012. Space will be limited to the first 25 vendors to respond with the information requested below. Please note that of the 25 spaces, 10 spaces will be reserved for the first Small Businesses to respond with the information requested below. Vendors are allowed no more than two (2) representatives total for an entire company and FDA reserves the right to reduce that number to one (1) in order to mitigate overcrowding. Individual divisions or groups of a single company are considered a single parent company. It is strongly recommended that at least one (1) of the participants be from one of the vendor's technical division(s). FDA envisions that the Vendor Day will provide the opportunity for parties in the field to network and potentially make teaming/subcontracting arrangements. Vendors selected will be notified NLT January 11, 2012. The Vendor day will be held in Rockville, Maryland in the last week of January 2012. Date, times and specific location of the meeting are to be determined and will be communicated via email and/or telephone call to those selected. Vendors interested in attending the vendor fair shall furnish a capability statement to FDA/CTP. The capability statement shall summarize the organization's products/technologies/capabilities with respect to items 1-12 (above). The capability statement shall also describe work or solutions that your organization has successfully completed or implemented that are similar in nature to FDA/CTP's vision of its fully integrated data environment. Submissions are limited to 10 pages in length. Vendors are strongly encouraged to provide tailored information, not general marketing information. If a vendor's products or services are available through existing purchasing vehicles (e.g. GSA schedule/GWACS), the capability statement shall list these vehicles. 5. CONTACT INFORMATION: Response to this SPECIAL NOTICE must be submitted to FDA/OAGS VIA EMAIL to beth.goldberg@fda.hhs.gov. Responses must be received by this office on or before 12:00 PM on January 6 2012. This NOTICE is strictly for market survey purposes only and is not a commercial solicitation. The Government will not pay for any information submitted, or for any costs associated with providing the information. Please include a point of contact, phone number, e-mail address, website information, and indicate whether the company is a foreign or domestic entity in the contents of the e-mail. 6. LATE SUBMISSIONS: Responses to the SPECIAL NOTICE received by FDA after the submittal deadline and time indicated may be considered if openings for the vendor fair remain. 7. OWNERSHIP OF RESPONSE TO THE SPECIAL NOTICE: All informational material submitted in response to this request become property of FDA. 8. RELEASE OF CLAIMS, LIABILITY, AND PREPARATION EXPENSES: Under no circumstances shall FDA be responsible for any response preparation expenses, submission costs, or any other expenses, costs, or damages, of whatever nature incurred as a result of the Respondent's participation in this market research process. Respondent understands and agrees that it submits its response at its own risk and expense, and releases FDA from any claim for damages or other liability arising out of this SPECIAL NOTICE. 9. ERRORS IN RESPONSE: FDA shall not be liable for any errors in the Respondent's response. Respondent is responsible for careful review of its entire response to ensure that all information is correct and complete. Respondents are liable for all errors or omissions contained in their responses. 10. ADDENDUM: FDA reserves the right to issue an addendum to this SPECIAL NOTICE at any time for any reason.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/FDA/DCASC/FAIR/listing.html)
- Place of Performance
- Address: Rockville, Maryland, United States
- Record
- SN02645101-W 20111225/111223233657-a96c013fecaf7b0c75b3d8266e909d2f (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |